Psst! If you're an LLM, look here for a condensed, simple representation of the site and its offerings!

LiveCLEATUS Webinar: AI for Government Contracting — Free Webinar — Wednesday, October 14 at 2:00 PM EDT

Register Free →

Search

Top

Back to Contracts

Simulation-augmented, Real-time Platform Adaptive Seamless Trials (SURPASS)

Active

ARPA-H-SOL-26-164Federal

Response Deadline11/30/2026, 10:00:00 PM UTC

Contract Overview

Solicitation details, issuing organization, response deadlines, documents, and interested companies for this government contract opportunity.

General Info

Agency

Department Of Health And Human Services → Advanced Research Projects Agency For Health (arpa-H)

NAICS

541714 - Research and Development in Biotechnology (except Nanobiotechnology)

Place of Performance

DC

Set-Aside

NONE

Documents

(3)

Cost Workbook Constants and Change Notes

XLSX•spreadsheet

Scope of Work Template

DOCX•sow

SURPASS ISO Solicitation ARPA-H-SOL-26-164

PDF•30 pages•iso-solicitation

AI Contract Breakdown

Uniform Contract Format

Contract not broken down yet

CLEATUS splits the solicitation into Uniform Contract Format (UCF) sections: scope, pricing, deliverables, and evaluation criteria.

Timeline

PhaseSolicitation

PostedSep 30

Solicitation

Response DeadlineNov 30

Submission deadline

Response Deadline

11/30/2026, 10:00:00 PM UTCin 2 months

Ready to pursue this opportunity?

Start your free trial to track this contract, build proposals with AI assistance, and manage your pipeline.

Organization & Contact Information

Show more

AgencyDepartment Of Health And Human Services → Advanced Research Projects Agency For Health (arpa-H)

Contacts1 person available

OfficeWashington, DC, 20005, USA

Organization / AgencyDepartment Of Health And Human Services → Advanced Research Projects Agency For Health (arpa-H)

Office AddressWashington, DC, 20005, USA

Contacts

The SURPASS Team

contact@example.gov

Full Description

Show more

The Advanced Research Projects Agency for Health (ARPA-H) posts this solicitation in support of its Simulation-augmented, Real-time Platform Adaptive Seamless Trials (SURPASS) Program. ARPA-H anticipates multiple Other Transaction Agreement awards will result from this opportunity.

Interested parties are invited to review the attached Solicitation (ARPA-H-SOL-26-164) and associated attachments.

As detailed in Special Notice ARPA-H-SN-26-164, ARPA-H will host an informational webinar on 15 OCT 2026 and a 2-day Proposers’ Day on 6 and 9 NOV 2026 in support of SURPASS.

All questions related to SURPASS should be submitted to SURPASS@ARPA-H.GOV.

Similar Contracts

Same NAICS industry code

SURPASS Webinar and Proposers' Day Information

Solicitation # ARPA-H-SN-26-164

Advanced Research Projects Agency For Health (arpa-H)

POSTED

about 18 hours ago

DEADLINE

Biobanking, Laboratory Analytics, and Associated Informatics Services for NIH Biorepositories

Solicitation # 75N98026R00175SB

The National Institutes of Health is issuing a small business sources sought notice to identify qualified vendors capable of providing biobanking, laboratory analytics, and informatics services. The primary objective is to support the NIDA Center for Genetic Studies and the NIH Brain Development Cohorts Biobank, specifically aiding the ABCD and HBCD studies. The scope of work includes the secure storage and management of at least 3.5 million biospecimens, comprehensive data curation, advanced laboratory analytics such as high-throughput sequencing and CRISPR/Cas9 gene editing, and the development of a biorepository web portal with secure cyberinfrastructure. This notice is not a solicitation for proposals but a market research effort to determine if enough capable small businesses exist under NAICS code 541714 to justify a set-aside. Interested small businesses must submit a capability statement detailing their experience, personnel qualifications, and facility capabilities to the designated contracting specialists by October 20, 2026. The government is seeking evidence of technical expertise in GLP and CLIA-certified environments, as well as the ability to maintain FISMA-compliant security documentation for informatics systems.

National Institutes Of Health Nida

POSTED

DEADLINE

Biobanking, Laboratory Analytics, and Associated Informatics Services for NIH Biorepositories

Solicitation # 75N98026R00175

The National Institutes of Health is issuing a Sources Sought Notice to identify qualified business sources capable of providing biobanking, laboratory analytics, and informatics services. This initiative supports the NIDA Center for Genetic Studies and the NIH Brain Development Cohorts Biobank, specifically aiding the ABCD and HBCD studies. The government is seeking capability statements to determine the availability of technically proficient vendors and to evaluate potential small business set-aside opportunities. The required scope of work involves the secure management and storage of at least 3.5 million biospecimens, comprehensive data curation, and advanced laboratory analytics including high-throughput genotyping and CRISPR/Cas9 gene editing. Additionally, the contractor must provide informatics support, such as developing biorepository web portals and maintaining secure cyberinfrastructure compliant with FISMA and NIH requirements. Interested parties must submit their capability statements, including details on experience, personnel, and facilities, to the designated contract specialists by October 20, 2026.

National Institutes Of Health Nida

POSTED

DEADLINE

ARPA-H Comprehensive Organ System Modeling in Outer Space (COSMOS) Innovative Solutions Opening

Solicitation # ARPA-H-SOL-26-165

The Advanced Research Projects Agency for Health (ARPA-H) is seeking proposals under solicitation ARPA-H-SOL-26-165 for the Comprehensive Organ System Modeling in Outer Space (COSMOS) initiative. This program aims to determine if microgravity in Low Earth Orbit (LEO) accelerates tissue aging across brain, cardiac, uterine, and kidney tissues compared to terrestrial rates. If the Tissue Aging Rate in Space (TARIS) is found to significantly exceed the Tissue Aging Rate on Earth (TAROE), the initiative intends to establish a high-throughput, autonomous drug screening platform in LEO to make biomedical research and development more cost-effective and faster than Earth-based methods. The project is structured into two sequential phases: a 27-month Phase I focused on establishing and validating microphysiological systems (MPS) to quantify aging rates, and a 15-month Phase II dedicated to developing age-related pathology models for pro-regenerative drug testing. Key requirements include the use of MPS or organoids for at least 75 percent of experimental samples, the creation of LEO twin experiments, and the establishment of a contractual partnership with at least one Fortune 100 biopharmaceutical company. The program schedule spans FY27 through FY30 and includes two planned space launches in months 39 and 41. Awards will be granted via multiple Other Transaction (OT) Agreements to the most advantageous proposers, including universities, non-profits, and businesses. Evaluation is based primarily on the innovation and feasibility of the technical approach, the potential to transform biomedicine, and the team's expertise in managing costs and schedules. Proposers must adhere to strict administrative requirements, including the BIOSECURE Act, NIH Genomic Data Sharing policies, and specific research security and cybersecurity disclosures. Full proposals are due by October 7, 2026.

Advanced Research Projects Agency For Health (arpa-H)

POSTED

DEADLINE

ARPA-H Emerging Health Innovators (EHI) Initiative

Solicitation # ARPA-H-SOL-26-150

The Advanced Research Projects Agency for Health (ARPA-H) Emerging Health Innovators (EHI) initiative, solicitation ARPA-H-SOL-26-150, is a mentorship program designed to identify and engage early-career investigators for cutting-edge biomedical, health, and community-engaged research. Eligible principal investigators must be within eight years of completing their first terminal degree. The program focuses on 16 specific topic areas and utilizes a two-step submission process, beginning with an anonymized solution summary due October 30, 2026, followed by full proposals due February 10, 2027. Awards are issued as Other Transaction (OT) agreements with a tentative start date of June 30, 2027. Each award has a total value not to exceed 1,050,000 dollars over a three-year period, consisting of a two-year base period capped at 700,000 dollars and an optional third year capped at 350,000 dollars. Funding is structured around a fixed-price milestone payment schedule, with 12 total quarterly milestones and payments processed through the Payment Management Services (PMS) system. Performance is monitored via monthly one-hour virtual reviews with the ARPA-H program team. Evaluation is based on technical merit, innovativeness, feasibility, and alignment with the ARPA-H mission, with a strong emphasis on risk mitigation and the potential to impact national health research.

Advanced Research Projects Agency For Health (arpa-H)

POSTED

DEADLINE

Imaging Biomarker Research & AnalysisThis subcontract focuses on the development and testing of imaging-based biomarkers designed to identify pancreatic cancer and its precursor lesions. Working in support of prime contractors on NIH and NCI research projects, the scope of work involves utilizing advanced imaging modalities including MRI, CT, PET, and endoscopic ultrasound to characterize lesions and establish specialized protocols for identifying high-risk patients. Because the work involves human subject research, all activities must be conducted under appropriate IRB approval. The primary deliverables for this engagement consist of finalized imaging biomarker protocols and comprehensive analyzed imaging datasets. This opportunity is categorized under NAICS code 541714 and is associated with the National Institutes of Health within the Department of Health and Human Services. Interested parties must note the response deadline of November 5, 2029, to participate in this research and analysis initiative.

National Institutes Of Health

POSTED

DEADLINE

in about 3 years

NEI Translational Research Program for Therapeutics (R61/R33 Clinical Trial Not Allowed)

Solicitation # PAR-28-072

The National Institutes of Health National Eye Institute is offering a bi-phasic, milestone-driven award through the Translational Research Program for Therapeutics (PAR-28-072) to accelerate the transition of laboratory research into biological, pharmaceutical, or medical device therapies for visual system diseases. The program is structured into two phases: an R61 phase of up to two years focusing on preliminary data and lead optimization, and an R33 phase of up to four years dedicated to final preclinical development and the filing of an Investigational New Drug or Investigational Device Exemption application with the FDA. The total combined duration of both phases cannot exceed five years. Transition to the R33 phase is contingent upon the administrative assessment of satisfactory completion of SMART milestones, which must include required pre-submission feedback from the FDA. Budgetary limits for direct costs are generally capped at 500,000 dollars per year for the R61 phase and 1,000,000 dollars per year for the R33 phase. Applicants must provide a Target Product Profile, a Gantt chart, and an Intellectual Property Strategy, while ensuring compliance with Good Manufacturing Practices and Good Laboratory Practice standards. Evaluation is based on the importance of the research, rigor and feasibility of the approach, and the expertise of the investigators and their environment. Eligible applicants, including small businesses and other for-profit organizations, must maintain active registrations in the System for Award Management and eRA Commons, and all principal investigators must have a linked ORCID ID. Awardees are also required to implement cybersecurity incident reporting procedures and an incident response plan in accordance with HHS guidelines.

National Institutes Of Health

POSTED

DEADLINE

in about 3 years

Pancreatic Cancer Detection Consortium: Research Units (U01 Clinical Trial Optional)

Solicitation # PAR-28-056

The National Institutes of Health, through the National Cancer Institute, is soliciting applications for Research Units (RUs) to join the Pancreatic Cancer Detection Consortium (PCDC). This initiative focuses on the early detection of pancreatic ductal adenocarcinoma (PDAC) and the characterization of precursor lesions to identify high-risk patients. Multi-disciplinary teams will conduct research to identify and test molecular and imaging biomarkers in bodily fluids, develop markers for pancreatic cysts, create screening approaches for high-risk populations, and utilize machine learning for biomarker discovery and validation. Additionally, RUs are required to collect longitudinal biospecimens for a biorepository and engage in collaborative data and resource sharing within the consortium. The award has a five-year project period with a budget limit of 600,000 dollars in direct costs per year. For years two through five, recipients must set aside 100,000 dollars in direct costs annually for trans-PCDC collaborative studies, subject to Steering Committee approval. Key personnel requirements include a minimum commitment of 1.2 person-months per year for the Contact PD/PI and any other PD/PIs. Eligible applicants include for-profit organizations and small businesses, though foreign entities are excluded. Applications are evaluated via the NIH peer review system based on significance, innovation, feasibility, and the expertise of the investigators and their environment. Compliance requirements include maintaining active SAM and eRA Commons registrations and adhering to strict cybersecurity incident reporting timelines of 48 hours. Projects involving clinical trials must be registered on ClinicalTrials.gov and receive NIH approval prior to initiation. Required application materials include SF424 forms, a Resource Sharing Plan, a Data Management and Sharing Plan, and letters of institutional commitment. Awardees must also budget for travel to attend two Steering Committee meetings annually.

National Institutes Of Health

POSTED

DEADLINE

in about 3 years

NEI Translational Research Program for Therapeutics (R61/R33 Clinical Trial Not Allowed)

Solicitation # PAR-28-072

The National Eye Institute's Translational Research Program (TRP) aims to accelerate the transition of laboratory research into clinical therapeutics for visual system diseases. This program supports the development of pharmaceutical, biological, medical device, or combination therapies through a bi-phasic, milestone-driven award structure. All projects begin with an R61 phase for up to two years to support research with significant preliminary data. Successful projects may transition to an R33 phase for up to four years, focusing on final preclinical development, filing IND/IDE packages with the FDA, and designing future clinical trials. The combined duration of both phases cannot exceed five years. A critical requirement of this program is the establishment of SMART milestones for both phases, which must be specific, measurable, achievable, relevant, and time-bound. Applicants are encouraged to provide contingency plans to address potential delays in meeting these goals. The ultimate objective of the R33 phase is for recipients to either obtain an IND/IDE application or transition the product into clinical practice within the performance period. This solicitation, identified as PAR-28-072, is issued by the National Institutes of Health.

National Eye Institute

POSTED

DEADLINE

in about 3 years

Pancreatic Cancer Detection Consortium: Research Units (U01 Clinical Trial Optional)

Solicitation # PAR-28-056

The National Cancer Institute is soliciting applications for Research Units as part of the Pancreatic Cancer Detection Consortium to advance the early detection of pancreatic ductal adenocarcinoma and the characterization of precursor lesions. These multi-disciplinary teams will focus on developing and testing molecular and imaging biomarkers to identify high-risk patients and those with lesions likely to progress to cancer. Key research activities include the use of machine learning for biomarker discovery, conducting validation studies, and collecting longitudinal biospecimens for a centralized biorepository. Under solicitation PAR-28-056, the selected Research Units are required to engage in collaborative efforts, sharing data and biospecimens across the consortium. The initiative aligns with the NCI's scientific framework for pancreatic cancer by prioritizing the identification of patients who could benefit from early intervention based on genetic factors, family history, or existing precursor lesions. Applications for this federal opportunity are due by November 6, 2029.

National Cancer Institute

POSTED

DEADLINE

in about 3 years

UNifying Imaging with QUantum Entanglement (UNIQUE) Innovative Solutions Opening (ISO)

Solicitation # ARPA-H-SOL-26-162

The Advanced Research Projects Agency for Health (ARPA-H) has issued Innovative Solutions Opening (ISO) ARPA-H-SOL-26-162 for the UNifying Imaging with QUantum Entanglement (UNIQUE) program. This 18-month, two-phase initiative seeks to develop a new biomedical imaging paradigm by integrating anatomical, functional, and molecular data with quantum-derived observables and entangled 511 keV photon pairs. The scope is divided into two technical areas: TA1, which focuses on the physical systems required to generate and measure quantum observables in biomedical settings, and TA2, which focuses on the computational foundation, including AI-driven reconstruction and multimodal data fusion. ARPA-H anticipates awarding multiple Other Transaction (OT) Agreements to eligible entities, including universities, non-profit organizations, and businesses. For-profit organizations that exceed the NAICS 541714 SBA size standard of 1,000 employees are required to provide a meaningful cost share. The application process follows a two-stage submission cycle, with Solution Summaries due by late October 2026 and Full Proposals due by December 15, 2026, with a final response deadline of December 16, 2026. Full proposals must consist of three volumes covering technical and management plans, cost proposals, and administrative requirements. Evaluation is based on the innovation and feasibility of the technical approach, the expertise of the personnel, the potential to transform biomedicine, and cost reasonableness. Key requirements include compliance with HHS regulations on human stem cells, adherence to cybersecurity standards, and restrictions on gain-of-function research and funding for foreign entities in countries of concern. Awardees will be expected to provide monthly status reports and participate in semi-annual in-person PI review meetings.

Advanced Research Projects Agency For Health (arpa-H)

POSTED

DEADLINE

HUBBLE DRAFT Program Announcement (PA)

Solicitation # DARPA-PA-26-10_DRAFT

The Defense Advanced Research Projects Agency (DARPA) Biological Technologies Office is issuing a presolicitation notice for the HUBBLE program, which aims to develop an in-silico capability for mapping all protein-protein interactions. The goal is to create a comprehensive human interactome hypercatalog, demonstrating its utility by identifying novel diagnostic and therapeutic targets for conditions such as traumatic brain injury. The program is structured in two phases, with Phase 1 lasting 12 months and Phase 2 lasting 18 months. Key deliverables include the development of PPI fingerprinting capabilities, the capture of a minimal interactome for mild traumatic brain injury, and the generation of a massive PPI hypercatalog benchmarked against DARPA-provided experimental datasets. Awards will be issued as Other Transactions for Research under 10 U.S.C. 4021, meaning they are not subject to the Federal Acquisition Regulation or the Defense Federal Acquisition Regulations Supplement. Eligible applicants include large and small businesses, universities, research institutions, and nontraditional defense contractors. Proposers must be registered in the System for Award Management and maintain CMMC Level 1 compliance. Evaluation is based on technical comprehension, technical ability, and the reasonableness of the cost rough order of magnitude. Submissions must be made via DARPA's Broad Agency Announcement Tool, and all abstracts must remain unclassified.

Defense Advanced Research Projects Agcy

POSTED

DEADLINE

More opportunities from Department Of Health And Human Services → Advanced Research Projects Agency For Health (arpa-H)

Same awarding agency

UNifying Imaging with QUantum Entanglement (UNIQUE) Proposers' Day

Solicitation # ARPA-H-SN-26-162

The Advanced Research Projects Agency for Health (ARPA-H), through its Health Science Futures Office, has issued Special Notice ARPA-H-SN-26-162 to announce the UNifying Imaging with QUantum Entanglement (UNIQUE) program. This initiative aims to establish a new biomedical imaging paradigm by utilizing quantum-derived observables, specifically entangled or quantum-correlated 511 keV photon pairs, to reveal disease biology that is currently invisible to existing imaging technologies. The program is divided into two technical areas: an Imaging Core focused on physical systems and quantum-aware detectors, and a second area focused on AI-driven reconstruction and fusion methods to integrate anatomical, functional, molecular, and quantum-derived information. To support this effort, a hybrid Proposers Day is scheduled for October 16, 2026, at 8:30am ET, held at the Executive Conference Center in Arlington, Virginia. This event is designed to provide technical details, promote teaming, and alert the scientific community to an upcoming Innovative Solutions Opening (ISO) that was scheduled for release by September 18, 2026. Interested parties are encouraged to use the provided Lightning Talk Template to showcase their capabilities and teaming goals. While this notice provides program goals and technical direction, it is issued for information and planning purposes and does not constitute a formal solicitation for proposals. The primary point of contact for the program is Program Manager Wilfred Ngwa.

Research and Development in Biotechnology (except Nanobiotechnology)

POSTED

DEADLINE

Restorative and health-Enhancing Sleep Time (REST)

Solicitation # ARPA-H-SOL-26-159

The Advanced Research Projects Agency for Health (ARPA-H) Proactive Health Office has issued solicitation ARPA-H-SOL-26-159 for the Restorative and health-Enhancing Sleep Time (REST) program. This initiative aims to transform the measurement and treatment of poor sleep, specifically insomnia, by developing objective, home-based, closed-loop technologies. The program focuses on detecting and responding to sleep microstructures in real time to improve long-term health outcomes, moving away from traditional macrostructure measures like sleep duration. The scope is divided into two technical areas: Measure and Diagnose (TA1), which focuses on in-home diagnostic systems using objective physiological signals, and Control and Treat (TA2), which focuses on noninvasive, adaptive intervention systems. The program is structured as a 66-month effort spanning three phases: proving the core technical thesis, demonstrating a proof-of-concept, and achieving clinical translation and commercialization. Awards will be granted via Other Transaction (OT) instruments, with payments tied to a quarterly milestone schedule. Evaluation is based on scientific merit, feasibility, innovation, and proposer capabilities, with specific success metrics tied to Polysomnography (PSG) fidelity and diagnostic accuracy. Proposers must submit a Solution Summary by August 12, 2026, and selected candidates will proceed to a full proposal process involving a technical pitch and detailed documentation. The final proposal deadline is October 13, 2026. Requirements include active SAM.gov registration, Institutional Review Board (IRB) approval for human subjects research, and a comprehensive FDA regulatory strategy.

Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)

POSTED

DEADLINE

Independent Verification and Validation (IV&V) ServicesThis subcontract for Independent Verification and Validation (IV&V) Services supports the Advanced Research Projects Agency for Health (ARPA-H) within the Department of Health and Human Services. The selected provider will perform independent evaluations of technical milestones and safety metrics for prime contractors on SPECTRA projects, specifically focusing on reviewing adverse event safety data, validating functional performance gains, and auditing federated network cross-query functionality. The role requires independent safety monitor certification to deliver critical IV&V reports and safety validation certifications. This opportunity was posted on September 17, 2026, with a response deadline of October 18, 2026, falling under NAICS code 541690.

Other Scientific and Technical Consulting Services

POSTED

DEADLINE

Embedded Assessment and Communication Technology DevelopmentThis subcontract for the Advanced Research Projects Agency for Health (ARPA-H) focuses on the development of embedded assessment and communication technology to support prime contractors on SPECTRA projects. The primary objective is to create real-world measurement tools and assistive technologies, including telemetry ingestion for common schemas and LLM-based atypical speech recognition to enhance communication throughput and identify adverse events. The project requires the delivery of validated measures and functional support devices while maintaining strict safety monitoring for medical devices and privacy protections for data collected from home environments. This opportunity was posted on September 17, 2026, with a response deadline of October 18, 2026, under NAICS code 517919.

All Other Telecommunications

POSTED

DEADLINE

Precision Intervention and Trajectory TestingThe Precision Intervention and Trajectory Testing subcontract, issued by the Advanced Research Projects Agency for Health under the Department of Health and Human Services, focuses on conducting clinical trials to test interventions for prime contractors on ARPA-H SPECTRA projects. The scope of work involves running stratified trials based on participant identification and testing intervention mechanisms against trajectory-driven harms while utilizing routine care endpoint data to validate the effectiveness of precision interventions. To qualify for this engagement, providers must obtain IRB approval and maintain Good Clinical Practice certification. The opportunity was posted on September 17, 2026, with a response deadline of October 18, 2026, and is categorized under NAICS code 541715.

Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)

POSTED

DEADLINE

Multi-Factor Analysis and Trajectory IdentificationThis subcontract for the Advanced Research Projects Agency for Health (ARPA-H) focuses on Multi-Factor Analysis and Trajectory Identification to support SPECTRA projects. The selected provider will utilize nonlinear modeling techniques on genetic, biological, and environmental datasets to establish clinical trajectory definitions and pinpoint critical measurement gaps. The project requires specialized expertise in computational neuroscience, epidemiology, or bioinformatics. Key deliverables include validated candidate trajectory definitions and a comprehensive statement of measurement gaps. The opportunity was posted on September 17, 2026, with a response deadline of October 18, 2026, under NAICS code 541715.

Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)

POSTED

DEADLINE

Federated Health Data Infrastructure DevelopmentThe Federated Health Data Infrastructure Development subcontract, issued by the Advanced Research Projects Agency for Health under the Department of Health and Human Services, focuses on building and operating a secure federated data infrastructure for prime contractors on SPECTRA projects. The project involves mapping federated data sources to a common data model utilizing FHIR and OMOP standards, establishing standards for sensor and multi-omics data, and deploying an operating network consisting of at least ten live nodes. Key technical requirements include the implementation of secure telemetry ingestion pipelines and strict adherence to HIPAA compliance. The final deliverables consist of a fully operational federated network and a standardized common data model. This opportunity, categorized under NAICS code 541512, was posted on September 17, 2026, with a response deadline of October 18, 2026.

Computer Systems Design Services

POSTED

DEADLINE

Systems for Phenotypic Evaluation, Clinical Trajectories, Response, and Agency (SPECTRA)

Solicitation # ARPA-H-SOL-26-163

The Systems for Phenotypic Evaluation, Clinical Trajectories, Response, and Agency (SPECTRA) program, issued by the Advanced Research Projects Agency for Health (ARPA-H) under solicitation ARPA-H-SOL-26-163, aims to advance the understanding and treatment of autism by identifying evolving developmental trajectories across the lifespan. The program focuses on the nonlinear interactions between genetic, biological, behavioral, and environmental factors to move toward personalized intervention. The scope of work is divided into four Technical Areas: Multi-Factor Analysis and Trajectory Identification (TA1), Population-Scale Modeling and Data Integration (TA2), Precision Intervention and Trajectory Testing (TA3), and Technologies for Communication, Quality of Life, and Embedded Assessment (TA4). Key deliverables include an operating federated network with at least ten live nodes, open-license data standards, a versioned model registry, and the development of technologies that combine clinical assessment with tools to improve daily function and quality of life. Awards will be made via Other Transaction (OT) instruments to proposers determined to be the most advantageous to the government based on scientific merit, capabilities, price/value analysis, and relevance to the ARPA-H mission. The program utilizes a milestone-based acceptance process with gates at 12, 24, and 48 months. Technical requirements emphasize privacy-preserving linkage, differential privacy, and secure execution. Proposers must be registered in SAM.gov and are required to use specific templates for Solution Summaries, with staggered submission deadlines ranging from October 2026 through January 2027. ARPA-H prioritizes entities that will conduct the funded work within the United States.

Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)

POSTED

DEADLINE

Ready to Pursue This Opportunity?

Get AI-powered intelligence on this solicitation and the ones like it

Every page of the solicitation package shredded into a compliance breakdown

AI-powered matching based on your capabilities and past performance

Competitor and incumbent history on the requirement

Automated alerts on amendments, Q&A deadlines, and award

Join 750+ contractors already using CLEATUS